India's earnings outlook lags Asia; stock selection key: Emmer Capital's Manishi Raychaudhuri

India’s earnings outlook lags Asia; stock selection key: Emmer Capital’s Manishi Raychaudhuri

Indian investors should adopt a selective approach to equities as the country’s earnings growth outlook remains weaker than other major Asian markets, according to Manishi Raychaudhuri, Chief Executive Officer of Emmer Capital Partners. Raychaudhuri said India’s corporate earnings growth is likely to remain in single digits in the fiscal year 2026-27 (FY27), marking a third…

Read More
SoftBank slides 11%, the biggest drop in months as AI-fuelled rally hits a speed bump

SoftBank slides 11%, the biggest drop in months as AI-fuelled rally hits a speed bump

Shares of Japan’s SoftBank Group Corp. tumbled more than 11% on Thursday, June 4, tracking a broad sell-off in global technology stocks after overnight weakness on Wall Street triggered profit-booking across the sector. The decline spread across Asian technology names, with Taiwan Semiconductor Manufacturing Co. (TSMC) falling about 1.7%, while Taiwan’s Foxconn dropped more than…

Read More
Ceigall India signs ₹177 crore definitive pact with Neo Infra Fund for CMASH divestment

Ceigall India signs ₹177 crore definitive pact with Neo Infra Fund for CMASH divestment

Ceigall India Ltd has entered into a definitive agreement to divest its stake in Ceigall Malout Abohar Sadhuwali Highways Private Limited (CMASH), a road infrastructure asset in Punjab, to Neo Infra Income Opportunity Fund, marking another step in its ongoing asset monetisation programme. The transaction has been formalised through a Share Purchase Agreement (SPA) signed…

Read More
Lupin unit Nanomi to acquire remaining 43.38% stake in Philippines arm for up to $39.6 million

Lupin Receives USFDA approval for ranluspec biosimilar referencing Lucentis

Pharmaceutical firm Lupin Ltd on Thursday (June 4) said it has received approval from the United States Food and Drug Administration (USFDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech. The company said Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vial and pre-filled syringe (PFS) presentations….

Read More
Kolte-Patil Q4 sales at ₹714 cr, collections hit record ₹834 cr; FY26 sales at ₹2,605 cr

Kolte-Patil Developers faces ₹64 crore GST demand notice from Maharashtra tax authority

Realty firm Kolte-Patil Developers Ltd on Thursday (June 4) said it has received intimations from the Office of the Assistant Commissioner of State Tax, Mumbai, for ascertainment of GST liability amounting to ₹64.41 crore, including interest and penalties. The company said the communication was received on June 3, 2026, and pertains to financial years from…

Read More